Named Bioactive Compounds · Compound
Diosmetin (Flavonoid)
Strong Evidenceflavonoid
Hermetica Superfood Encyclopedia
Diosmetin is a citrus flavonoid found in citrus peels and mint that exhibits antioxidant and anti-inflammatory properties through modulation of cellular signaling pathways. This bioactive compound demonstrates potential therapeutic effects against oxidative stress and inflammatory conditions in preliminary research.
Diosmetin is an O-methylated flavone (C₁₆H₁₂O₆) naturally occurring in citrus fruits as the aglycone of diosmin, and also found in plants like Caucasian vetch. It has the structure 5,7,3′-trihydroxy-4′-methoxyflavone, also known as luteolin 4'-methyl ether, with a molecular weight of 300.26 g/mol.
No human clinical trials, RCTs, or meta-analyses for diosmetin were identified in the research. While cytochrome P450 mechanisms are referenced (PMIDs: 10681376, 11555828, 12865317, 15258110, 20972997), these relate to general enzyme systems rather than diosmetin-specific human trials.
No clinically studied dosage ranges are available for diosmetin in any form (extract, powder, or standardized preparation). Consult a healthcare provider before starting any new supplement.
Diosmetin (3',5,7-trihydroxy-4'-methoxyflavone; C₁₆H₁₂O₆; MW 300.26 g/mol) is a methylated flavone aglycone, not a macronutrient source. It is the aglycone of diosmin (diosmetin-7-O-rutinoside). Key bioactive characteristics: • Found naturally in citrus fruits (especially lemon and orange peel), olive leaves (Olea europaea), and herbs such as Laminaceae species; typical concentrations in dietary sources range from 0.1–5 mg/g dry weight depending on plant part and species. • Oral bioavailability is generally low as a free aglycone (~5–15% estimated), limited by poor aqueous solubility (~0.02 mg/mL in water at 25°C), extensive Phase II conjugation (glucuronidation and sulfation in the intestinal wall and liver), and P-glycoprotein-mediated efflux. • Diosmin (the glycoside prodrug) is partially converted to diosmetin by intestinal microbiota and brush-border enzymes, improving effective delivery. • LogP ~2.0–2.4, indicating moderate lipophilicity; absorption may be enhanced by co-administration with lipids or formulation as nanoparticles/phospholipid complexes. • Primary circulating metabolites include diosmetin-3'-O-glucuronide and diosmetin-7-O-glucuronide; plasma half-life estimated at 2–4 hours in rodent models. • Contains no appreciable calories, protein, fat, carbohydrates, fiber, vitamins, or minerals at pharmacologically relevant doses (typically studied at 10–100 mg/kg in animal models or 50–500 µM in cell culture). • Key functional groups: catechol-like B-ring hydroxyl (3'-OH) contributing to radical scavenging (DPPH IC₅₀ ~15–30 µM), C-4 carbonyl and C2-C3 double bond enabling electron delocalization, and 4'-OCH₃ group modulating receptor binding and metabolic stability. • Reported to chelate transition metal ions (Fe²⁺, Cu²⁺) at the 5-OH/4-oxo site, contributing to indirect antioxidant effects. • Weak TrkB (tropomyosin receptor kinase B) partial agonist with EC₅₀ in the low micromolar range (~1–10 µM in vitro), relevant to potential neurotrophic signaling. • No established RDA, DRI, or Tolerable Upper Intake Level; not classified as an essential nutrient.
Diosmetin exerts its biological effects by scavenging reactive oxygen species and inhibiting pro-inflammatory enzymes including cyclooxygenase and lipoxygenase. The compound modulates nuclear factor-kappa B (NF-κB) signaling pathways, reducing expression of inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6. Additionally, diosmetin activates antioxidant defense systems through the Nrf2 pathway, enhancing cellular protection against oxidative damage.
Current evidence for diosmetin comes primarily from in vitro and animal studies, with limited human clinical data available. Laboratory research has demonstrated antioxidant activity with IC50 values ranging from 25-50 μM in various cell models. Anti-inflammatory effects have been observed in rodent studies at doses of 10-25 mg/kg body weight. No large-scale human trials have been conducted to establish clinical efficacy or optimal dosing regimens for therapeutic applications.
Diosmetin appears to have low acute toxicity based on animal studies, with LD50 values exceeding 2000 mg/kg in rodents. No specific drug interactions have been documented, though theoretical interactions may occur with anticoagulant medications due to potential effects on platelet function. Safety during pregnancy and lactation has not been established through clinical studies. Individuals with citrus allergies should exercise caution when considering diosmetin supplements.
